Seed Round

HemostOD raises CHF 1.7M in seed round financing.

This seed funding round enables us to build our core team, establish our laboratory facilities, and advance our proprietary platelet manufacturing platform towards clinical validation. The investment represents strong confidence from our investors in our vision to revolutionize platelet therapy.

The funding will accelerate our research and development efforts as we work towards our first clinical trial, expected in 2027.